The 1 Wall Street analysts covering Decoy Therapeutics, Inc. hold a median 12-month price target of $3 — +191.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 21 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Decoy Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (9): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DCOY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +191.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Jan 2026 | Ladenburg Thalmann | Initiates | Buy | $2.50 |
| 23 Jan 2026 | Ladenburg Thalmann | Initiates | Buy | — |
| 11 Mar 2022 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $4.00 |
| 25 Aug 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 June 2020 | Benchmark | Initiates | Speculative Buy | — |
| 27 Apr 2020 | Ladenburg Thalmann | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DCOY appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Decoy Therapeutics, Inc. returned −97.7% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 12% of US stocks
Cheaper than 89% of US stocks
Cheaper than 58% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 2% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Decoy Therapeutics, Inc. has a market value of $2.6M and an enterprise value of −$7.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$14.4M.
Free cash flow in the twelve months to 30 June 2026: −$8.9M.
Trailing P/E: 0.1×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Decoy Therapeutics, Inc. employs 11 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Decoy Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Decoy Therapeutics announced that CEO Rick Pierce will deliver an investor presentation at The Small Cap Showcase on Thursday, October 1 in New York. The presentation is scheduled as part of the company's participation in the event.
Why it matters — DCOY watchers may be interested as the presentation offers the CEO a platform to communicate with the investment community about the company.
Decoy Therapeutics reported preclinical data for its DCOY-CoV program, showing that a single intranasal dose maintained drug levels above designed therapeutic concentrations for up to seven days in nasal mucosal and lung tissue, supporting once-weekly intranasal dosing. The program is designed to protect against endemic human coronaviruses including OC43, 229E, NL63, HKU1, and SARS-CoV-2 in high-risk populations.
Why it matters — The preclinical PK data may support a differentiated once-weekly intranasal dosing profile for DCOY-CoV and validate progress in addressing coronaviruses in high-risk immunocompromised and COPD patients.
Decoy Therapeutics, Inc. issued a correction to its September 22, 2026 press release announcing the Company's warrant inducement transaction. The Company published the correction on the same date via PRNewswire.
Why it matters — The correction may affect how investors interpret the details of Decoy's warrant inducement transaction announced that day.
Decoy Therapeutics announced a warrant inducement agreement with an existing institutional investor for the immediate exercise of Series B Milestone Warrants covering 1,184,434 warrants, priced at-the-market under Nasdaq rules for approximately $3.85 million in gross proceeds.
Why it matters — This transaction brings in new capital to Decoy and provides clarity on the company's near-term funding and dilution from warrant exercises.
Decoy Therapeutics announced a refined corporate strategy to explore its D-MAVs for additional candidates, including a pan-filovirus program pursuing the FDA Animal Rule pathway for expedited regulatory approval. The company noted that next-generation D-MAVs demonstrated potent in vitro activity against Ebola Zaire and Marburg viruses, targeting eligibility for a high-value FDA Priority Review Voucher.
Why it matters — A DCOY watcher would care because the expanded pipeline, FDA Animal Rule pathway, and potential Priority Review Voucher eligibility could broaden Decoy's antiviral platform beyond respiratory threats.
The 1 Wall Street analysts covering Decoy Therapeutics, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Decoy Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Decoy Therapeutics, Inc. 19 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Oct 2026, Decoy Therapeutics, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +191.3% from the last close, and Ticker Nerd's factor model ranks Decoy Therapeutics, Inc. 19 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Decoy Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCOY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.
Decoy Therapeutics, Inc. returned -97.7% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Decoy Therapeutics Inc. is a pre-clinical biotechnology company focused on discovering and developing peptide conjugate therapeutics.
The most recent item we track (GlobeNewsWire, 30 Sept 2026): "Decoy Therapeutics to Present at The Small Cap Showcase". Decoy Therapeutics announced that CEO Rick Pierce will deliver an investor presentation at The Small Cap Showcase on Thursday, October 1 in New York. The presentation is scheduled as part of the company's participation in the event.
Decoy Therapeutics Inc. is a pre-clinical biotechnology company focused on discovering and developing peptide conjugate therapeutics. Its core work centers on the IMP3ACT platform, which uses machine learning, artificial intelligence, and rapid synthesis methods to design and manufacture peptide-based drug candidates with improved targeting and development efficiency. The company’s current programs emphasize infectious diseases, with a particular focus on respiratory viruses, as well as oncology and other high-unmet-need areas. Decoy Therapeutics is developing Designable Multi-Antivirals, a class of antiviral candidates intended to address shared viral mechanisms across multiple virus families. The company also maintains a broader pipeline that includes legacy therapeutic assets alongside its newer antiviral efforts. Headquartered in Houston, Texas, Decoy Therapeutics operates as a research-driven biotechnology business aimed at advancing novel therapeutic platforms for difficult-to-treat diseases.
CEO Mr. Frederick E. Pierce II · 11 employees · United States · https://decoytx.com
